Commercially bioavailable proprietary technologies and their marketed products

Drug Discovery Today

Volumn 18, Issue 19-20, 2013, Pages 936-949

  Alam, Mohd Aftab ^a   Al Jenoobi, Fahad I ^a   Al Mohizea, Abdullah M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BOSWELLIC ACID; CANDESARTAN HEXETIL; CAPTOPRIL; CASPEROME; CATECHOL DERIVATIVE; CEFDITOREN PIVOXIL; CEFOTIAM; CODANTHRAMER; CURCUMIN; CYCLODEXTRIN; CYCLOSPORIN A; DANAZOL; DEXMETHYLPHENIDATE; EPIGALLOCATECHIN GALLATE; ETHOSUXIMIDE; FENOFIBRATE; FIRTECAN; GLIMEPIRIDE PLUS PIOGLITAZONE; GLYCERYL TRINITRATE; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; GREENSELECT; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; LIMAPROST; LIPOSTABIL; MACROGOL; MACROGOL 6000; MEGESTROL ACETATE; MERIVA; METHYLPHENIDATE; MORPHINE SULFATE; NANOCRYSTAL; NEUROSILIN; NICOTINE GUM; NIFEDIPINE; NIMESULIDE; OLEASELECT; OMEBETA; PALIPERIDONE; PEPPERMINT OIL; PHOSPHATIDYLCHOLINE; PIASCLEDINE; PIROXICAM BETA CYCLODEXTRIN; POLOXAMER; POLYSORBATE 80; POLYVINYL ALCOHOL; POVIDONE; PROSTAGLANDIN E2; RAPAMYCIN; REPAGLINIDE; SABAL EXTRACT; SILIBININ; SILICON DIOXIDE; SILIPHOS; SOLICAM; SOLUFEN; SOLUPLUS; SP1063C; SUSTENNA; TELMISARTAN; TIAPROFENIC ACID; TIZANIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VEFEND; ZIPRASIDONE;

AREA UNDER THE CURVE; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; NANOTECHNOLOGY; PATENT; PHYSICAL CHEMISTRY; REVIEW; TECHNOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HUMANS; MARKETING; NANOPARTICLES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84884593667     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.007     Document Type: Review

References (113)

1. P.L. Toutain, and A. Bousquet-Melou Bioavailability and its assessment J. Vet. Pharmacol. Ther. 27 2004 455 466 (Pubitemid 39665132)
2. J.H. Lin, and A.Y. Lu Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol. Rev. 49 1997 403 449 (Pubitemid 28030947)
3. M.N. Martinez, and G.L. Amidon A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J. Clin. Pharmacol. 42 2002 620 643 (Pubitemid 34547446)
4. G.E. Granero, and G.L. Amidon Stability of valacyclovir: implications for its oral bioavailability Int. J. Pharm. 317 2006 14 18 (Pubitemid 43866338)
5. E.S. Kostewicz Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51 (Pubitemid 38195327)
6. K.S. Lown Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J. Clin. Invest. 99 1997 2545 2553 (Pubitemid 27227734)
7. S.J. Choi Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin Arch. Pharm. Res. 34 2011 309 315
8. A.S. Darwich Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the 'Advanced Dissolution, Absorption, Metabolism (ADAM)' model Curr. Drug Metab. 11 2010 716 729
9. J. Zhu In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator Drug Metab. Pharmacokinet. 25 2010 477 486
10. C. Murphy Optimization of a dual mechanism gastrofloatable and gastroadhesive delivery system for narrow absorption window drugs AAPS PharmSciTech 13 2012 1 15
11. W. Liu Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin Toxicol. Appl. Pharmacol. 265 2012 316 324
12. H. Suzuki, and Y. Sugiyama Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine Eur. J. Pharm. Sci. 12 2000 3 12
13. G.L. Amidon A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
14. Anon. Waiver of In-Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System 2000 FDA Guidance for Industry
15. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26 (Pubitemid 33653411)
16. D.N. Bikiaris Solid dispersions, Part I: Recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs Expert Opin. Drug Deliv. 8 2011 1501 1519
17. D.N. Bikiaris Solid dispersions, Part II: New strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs Expert Opin. Drug Deliv. 8 2011 1663 1680
18. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666 (Pubitemid 47299263)
19. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1996 1017 1025 (Pubitemid 26338912)
20. B.S. Abuasal Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability Lipids 47 2012 461 469
21. X.Q. Wang, and Q. Zhang pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs Eur. J. Pharm. Biopharm. 82 2012 219 229
22. Y.S.R. Krishnaiah Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs J. Bioequiv. Availab. 2 2010 028 036
23. P. Fasinu Diverse approaches for the enhancement of oral drug bioavailability Biopharm. Drug Dispos. 32 2011 185 209
24. ®) Altern. Med. Rev. 10 2005 193 203 (Pubitemid 41384033)
25. P.M. Kidd Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts Altern. Med. Rev. 14 2009 226 246
26. A. Semalty Supramolecular phospholipids-polyphenolics interactions: the phytosome strategy to improve the bioavailability of phytochemicals Fitoterapia 81 2010 306 314
27. Y. Song Preparation and properties of a silybin-phospholipid complex Pharmazie 63 2008 35 42 (Pubitemid 351155202)
28. Ezio, B. et al. Inverni Della Beffa SPA. Complexes of flavanolignanes with phospholipids, preparation thereof and associated pharmaceutical compositions. EP0209038 B1
29. Giori, A. and Franceschi, F. Indena SPA. Phospholipid complexes of curcumin having improved bioavailability. WO 2007/101551 or EP 1837030 A1
30. ®, a curcumin phosphatidylcholine complex, during extended administration in osteoarthritis patients Altern. Med. Rev. 15 2010 337 344
31. ®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis Panminerva Med. 52 Suppl. 1 2010 55 62
32. T.H. Marczylo Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine Cancer Chemother. Pharmacol. 60 2007 171 177 (Pubitemid 46742531)
33. Franceschi, F. and Giori, A. Indena SPA. Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability. WO 2007/118631
34. ®) of Boswellia extract Fitoterapia 84C 2012 89 98
35. P. Pietta Relationship between rate and extent of catechin absorption and plasma antioxidant status Biochem. Mol. Biol. Int. 46 1998 895 903 (Pubitemid 29004600)
36. H. Chen Nanonization strategies for poorly water-soluble drugs Drug Discov. Today 16 2011 354 360
37. J.U. Junghanns, and R.H. Muller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
38. R. Shegokar, and R.H. Muller Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives Int. J. Pharm. 399 2010 129 139
39. T. Gulsun Nanocrystal technology for oral delivery of poorly water-soluble drugs FABAD J. Pharm. Sci. 34 2009 55 65
40. S.V. Sawant Drug nanocrystals: novel technique for delivery of poorly soluble drugs Int. J. Sci. Innovat. Discov. 1 2011 1 15
41. A. Bajaj Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan AAPS PharmSciTech 13 2012 1331 1340
42. Liversidge, G.G. et al. Sterling Drug Inc. Surface modified drug nanoparticles. 5145684
43. V.B. Patravale Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 56 2004 827 840 (Pubitemid 38885975)
44. E. Merisko-Liversidge, and G.G. Liversidge Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology Adv. Drug Deliv. Rev. 63 2011 427 440
45. C.M. Keck, and R.H. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16 (Pubitemid 41736019)
46. X. Pu Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs Curr. Nanosci. 5 2009 417 427
47. Muller, R.H. et al. Medac Gesellschaft Fur Klinische Spezialpraparate. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. 5858410
48. Kipp, J.E. et al. Baxter International Inc. Method for preparing submicron particle suspensions. 6884436
49. L. Al Shaal Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation Int. J. Pharm. 420 2011 133 140
50. H. Rachmawati Development of curcumin nanocrystal: physical aspects J. Pharm. Sci. 102 2013 204 214
51. C. Detroja Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study Sci. Pharm. 79 2011 635 651
52. Dobetti L. et al. Eurand Pharmaceuticals Ltd. Drug activation process and vibrational mill therefor. 7793871
53. S. Ellul Bioenhancement technologies improve absorption of insoluble drugs in oral dosage forms Int. Pharm. Rev. 2007 2 3
54. Chen, X. et al. Board of Reagents. Preparation of drug particles using evaporation precipitation into aqueous solutions. EP 1335705 B1
55. X. Chen Rapid dissolution of high-potency danazol particles produced by evaporative precipitation into aqueous solution J. Pharm. Sci. 93 2004 1867 1878 (Pubitemid 38823712)
56. T. Purvis Cryogenic liquids, nanoparticles, and microencapsulation Int. J. Pharm. 324 2006 43 50 (Pubitemid 44548287)
57. J.M. Vaughn Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies Drug Dev. Ind. Pharm. 32 2006 559 567
58. Holt, K. et al. Pharmanova Inc. Nanoparticle pharmaceutical formulations. 20110268775
59. R. Laitinen Emerging trends in the stabilization of amorphous drugs Int. J. Pharm. 2012 10.1016/j.ijpharm.2012.04.066
60. V. Ambrogi Use of SBA-15 for furosemide oral delivery enhancement Eur. J. Pharm. Sci. 46 2012 43 48
61. K.K. Qian, and R.H. Bogner Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, Part 1: Thermodynamics of spontaneous amorphization J. Pharm. Sci. 100 2011 2801 2815
62. M. Van Speybroeck Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica Eur. J. Pharm. Sci. 41 2010 623 630
63. Z. Wang Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate release pellets supported on SBA-15 mesoporous silica Int. J. Nanomed. 7 2012 5807 5818
64. T. Fu Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials J. Nanosci. Nanotechnol. 12 2012 3997 4006
65. Y. Zhang Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs Mol. Pharm. 9 2012 505 513
66. R. Mellaerts Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica Eur. J. Pharm. Biopharm. 69 2008 223 230
67. B. Chen In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation Int. J. Nanomed. 7 2012 199 209
68. K. Miyake Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin Pharm. Dev. Technol. 5 2000 399 407 (Pubitemid 30602848)
69. F. Hirayama, and K. Uekama Cyclodextrin-based controlled drug release system Adv. Drug Deliv. Rev. 36 1999 125 141 (Pubitemid 29074480)
70. G.B. Fregnan, and F. Berte Enhancement of specific biological activity of dipyridamole by complexation with beta-cyclodextrin Pharmacology 40 1990 96 102 (Pubitemid 20105230)
71. S. Basavaraj Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component Pharm. Dev. Technol. 11 2006 443 451 (Pubitemid 44852426)
72. L.S. Ribeiro Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine J. Pharm. Sci. 96 2007 2018 2028 (Pubitemid 47280098)
73. R. Kalaiselvan Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques Pharmazie 62 2007 604 607 (Pubitemid 47326167)
74. O. Radia Preparation of meloxicam-β-cyclodextrin-polyethylene glycol 6000 ternary system: characterization, in vitro and in vivo bioavailability Pharm. Dev. Technol. 17 2012 632 637
75. H.X. Lv Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex Pharmazie 67 2012 46 53
76. V. Barillaro Oral bioavailability in pigs of a miconazole/hydroxypropyl- gamma-cyclodextrin/l-tartaric acid inclusion complex produced by supercritical carbon dioxide processing AAPS J. 7 2005 E149 E155
77. M. Piette Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions Eur. J. Pharm. Sci. 28 2006 189 195 (Pubitemid 43766102)
78. M. Lahiani-Skiba Solubility and dissolution rate of progesterone- cyclodextrin-polymer systems Drug Dev. Ind. Pharm. 32 2006 1043 1058 (Pubitemid 44521822)
79. N. Ozdemir, and J. Erkin Enhancement of dissolution rate and bioavailability of sulfamethoxazole by complexation with β-cyclodextrin Drug Dev. Ind. Pharm. 38 2012 331 340
80. T. Taupitz New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin Eur. J. Pharm. Biopharm. 84 2013 208 218
81. Fages, J. et al. Pierre Fabre Medicament. Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid. 7390411
82. Freiss, B. and Lochard, H. Pierre Fabre Medicament. Complex containing mequitazine, a cyclodextrin and an interaction agent. 7749982
83. Stella, V.J. and Rajewski, R. University of Kansas. Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof. 5376645
84. Antle, V. CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions. 7635773
85. James, D.P. et al. CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof. 7629331
86. Alakhov, V. et al. Supratek Pharma, Inc. Cyclopolysaccharide compositions. WO2011/104625
87. Alakhov, V. et al. Supratek Pharma, Inc. Bendamustine anionic-cationic cyclopolysaccharide compositions. WO2012/127277
88. Popek, T. et al. (2010) Bendamustine cyclopolysaccharide compositions. 20100216858
89. C. Dahlberg Surface composition and contact angle relationship for differently prepared solid dispersions Eur. J. Pharm. Biopharm. 70 2008 478 485
90. M.A. Alam Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates Expert Opin. Drug Deliv. 9 2012 1419 1440
91. ® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo Eur. J. Pharm. Sci. 45 2012 336 343
92. A.H. Vadher Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac AAPS PharmSciTech 10 2009 606 614
93. J. Maclean Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin J. Pharm. Sci. 100 2011 3332 3344
94. S.A. Hailu, and R.H. Bonger Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers J. Pharm. Sci. 98 2009 3358 3372
95. D. Bahl, and R.H. Bogner Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism Pharm. Res. 23 2006 2317 2325 (Pubitemid 44511512)
96. M.K. Gupta Formation of physically stable amorphous drugs by milling with Neusilin J. Pharm. Sci. 92 2003 536 551 (Pubitemid 36258968)
97. D. Schachter Solid solution of a poorly soluble model drug in a phase-separated polymer matrix: melt-prepared dispersions based on POLYOX™ WSR The 30th Annual Meeting of the Controlled Release Society Glasgow, UK 2003
98. Sherman, B.C. Bernard Charles Sherman. Pharmaceutical composition comprising fenofibrate. 6444225
99. Fort, J.J. et al. Abbott Laboratories. Solid dispersion pharmaceutical formulations. 7364752
100. Holm, P. Lifecycle Pharma A/S. Solid dispersions comprising tacrolimus. 7994214
101. Berndl G. et al. Abbott Laboratories. Solid pharmaceutical dosage form. 8025899
102. M. Patel Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques AAPS PharmSciTech 9 2008 1262 1269
103. R. Chen Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique Chem. Pharm. Bull. 56 2008 254 259 (Pubitemid 351463233)
104. A.C. Rumondor Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture AAPS PharmSciTech 12 2011 1209 1219
105. K. Pajula Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram Mol. Pharm. 7 2010 795 804
106. S. Janssens, and G. Van den Mooter Review: physical chemistry of solid dispersions J. Pharm. Pharmacol. 61 2009 1571 1586
107. Holm P. et al. Lifecycle Pharma A/S. Controlled agglomeration. 7217431
108. E.T. Cole Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration Adv. Drug Deliv. Rev. 60 2008 747 756
109. K. Kavitha Effect of dissolution rate by liquisolid compact approach: an overview Pharm. Lett. 3 2011 71 83
110. B.M. El-Houssieny Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits Biosci. Trends 4 2010 17 24
111. Spireas, S. Liquisolid systems and methods of preparing same. 6423339
112. Spireas, S. and Bolton S.M. Liquisolid systems and methods of preparing same. 5968550
113. K.A. Khaled In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs Int. J. Pharm. 222 2001 1 6 (Pubitemid 32525783)